This suggests that passive immunization with tau antibodies is often a viable therapeutic goal and that the CSF volume of p-tau262/356 or on the microtubule binding domain (MTBD) can function a beneficial biomarker of tau pathology to monitor tau therapeutics in clinical trials.A docking station can expand your connectivity solutions, allowing for